Aspen Neuroscience secured $115 million in Series C financing to support its autologous cell therapy program for Parkinson’s disease, expand manufacturing capacity and progress an ongoing clinical trial. The raise positions Aspen to enter a Phase 3‑focused pathway and to scale up manufacturing ahead of potential pivotal studies. Company statements highlighted the funding’s role in advancing personalized regenerative therapies and preparing for a potential IPO next year. Aspen said the capital will support clinical development, manufacturing scale‑up and regulatory interactions as it moves toward later‑stage testing.